Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) ROCE %: 8.91% (As of Mar. 2026)


SHSE:688336 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
85 GF Score
Price ¥53.10
GF Value ¥66.54
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sunshine Guojian Pharmaceutical (Shanghai) Co ROCE %?

Sunshine Guojian Pharmaceutical (Shanghai) Co SHSE:688336 +6.73% 85 ROCE % is 8.91% as of Mar. 2026. GuruFocus rates SHSE:688336 with a GF Score™ of 85/100 and a GF Value™ of ¥66.54 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 8.91%.

Sunshine Guojian Pharmaceutical (Shanghai) Co  (SHSE:688336) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sunshine Guojian Pharmaceutical (Shanghai) Co ROCE % Related Terms

Sunshine Guojian Pharmaceutical (Shanghai) Co ROCE % Historical Data

* Premium members only.

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Guojian Pharmaceutical (Shanghai) Co ROCE % Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.57 0.64 6.42 13.32 46.89

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.75 5.31 15.50 160.62 8.91
SHSE:688336
85GF Score
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Guojian Pharmaceutical (Shanghai) Co ROCE % Calculation

Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=3319.107/( ( (5965.027 - 316.908) + (8957.374 - 447.022) )/ 2 )
=3319.107/( (5648.119+8510.352)/ 2 )
=3319.107/7079.2355
=46.89 %

Sunshine Guojian Pharmaceutical (Shanghai) Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=765.7/( ( (8957.374 - 447.022) + (8948.305 - 277.049) )/ 2 )
=765.7/( ( 8510.352 + 8671.256 )/ 2 )
=765.7/8590.804
=8.91 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.91% mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a ROCE % of 8.91% as of Mar. 2026.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's ROCE % too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current ROCE % is 8.91%. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's ROCE % compare to VRTX and REGN?
Sunshine Guojian Pharmaceutical (Shanghai) Co's ROCE % of 8.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sunshine Guojian Pharmaceutical (Shanghai) Co's current ROCE % is 8.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥66.54, compared to a current price of ¥53.10 — trading 20.2% below its estimated fair value. The current ROCE % is 8.91%. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current ROCE % is 8.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued. The current stock price of ¥53.10 is trading 20.2% below its estimated GF Value™ of ¥66.54. GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.

Key valuation signals for SHSE:688336:

  • ROCE %: 8.91%
  • GF Value™: ¥66.54 vs. price of ¥53.10 (20.2% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Address No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
85GF Score

Get the complete analysis for SHSE:688336

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥53.10
Price
¥66.54
GF Value